Prognia
Drug Database
🇪🇺EU · EMAOpinion

Cenrifki(tolebrutinib)

Multiple Sclerosis, Chronic Progressive

Marketing Authorisation Holder: Sanofi Winthrop Industrie

INN: tolebrutinib

Indication

treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS) in adults

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Cenrifki — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.